Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 /HR metastatic breast cancer.
Matthew Loft, Sheau Wen Lok, Richard H De Boer, Laeeq Malik, Sally Greenberg, Belinda Yeo, Angelyn Anton, Louise M Nott, Gary Edward Richardson, Ian M Collins, Javier Torres, Frances Sarah Barnett, Bianca Alix Devitt, Peter Gibbs, Lucy Gately
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2020
1038 Background: The combination of dual anti-HER2 targeted therapy and chemotherapy is the current first line standard of care for HER2+ metastatic breast cancer. Endocrine therapy (ET) is the backbone of treatment in hormone receptor positive (HR+) disease, but the role of the addition of endocrine therapy following chemotherapy in HER2+/HR+ disease remains unclear as pivotal first line clinical trials excluded endocrine therapy use. Methods: Data from a multi-site community cohort of consecutive HER2+ metastatic breast cancer patients diagnosed between 1 January 2012 and 31 August 2019 was examined. Patients were treated at clinician discretion. The subset of patients eligible for this a..View full abstract